首页 > 最新文献

Reumatologia最新文献

英文 中文
Effect of low-calorie diet on psoriasis severity index, triglycerides, liver enzymes, and quality of life in psoriatic patients with non-alcoholic fatty liver disease. 低热量饮食对银屑病合并非酒精性脂肪性肝病患者银屑病严重程度指数、甘油三酯、肝酶和生活质量的影响
Q3 RHEUMATOLOGY Pub Date : 2023-01-01 DOI: 10.5114/reum/162995
Ali Mohamed Ali Ismail, Ahmad Elsayed Saad, Ramy Salama Draz

Introduction: Chronic-plaque psoriasis is a chronic inflammatory dermatological disease. Obesity comorbidities, including non-alcoholic fatty liver disease, are highly prevalent in patients with chronic-plaque psoriasis. Recently, weight loss has been a highly recommended intervention to improve the severity of psoriatic symptoms, psoriasis-induced chronic systemic inflammation, psoriasis-associated cardiovascular risk factors, quality of life, and the efficacy of anti-psoriatic drugs. This study was designed to assess the effect of a 12-week low-calorie-diet intervention on aspartate transaminase, psoriasis severity (assessed via Psoriasis Area and Severity Index - PASI), alanine transaminase, quality of life (assessed via Dermatology Life Quality Index - DLQI), triglycerides, waist circumference (WC), and body mass index (BMI) in class I obese men with chronic-plaque and non-alcoholic fatty liver disease.

Material and methods: Sixty men with age ≥ 18 years with class I obesity and with chronic plaque psoriasis and non-alcoholic fatty liver disease were included in the study. All participants were randomly assigned to one of two groups: the first group as the low-calorie-diet group (30 men received immunosuppressive drugs, followed a low-calorie diet, and increased their energy expenditure through a daily 15,000-step outdoor walking program for 12 weeks) and the second as the control group (30 men received immunosuppressive drugs only). The primary outcome consisted of the results of the area and severity index. Weight, BMI, WC, laboratory results such as triglycerides, liver enzymes (alanine transaminase and aspartate transaminase) as well as DLQI were considered as secondary outcomes.

Results: While no significant improvements were achieved in the measured variables of the control group, the low-calorie-diet group demonstrated significant improvement in all the measured variables.

Conclusions: The results of the present study confirmed that 12-week low-calorie-diet intervention controls BMI, increases the response of psoriasis to pharmacological agents and improves the quality of life. Diet interventions significantly control the elevated hepatic enzymes (aspartate and alanine transaminases) and triglycerides in male patients with chronic-plaque psoriasis and non-alcoholic fatty liver disease.

简介:慢性斑块型银屑病是一种慢性炎症性皮肤病。肥胖合并症,包括非酒精性脂肪性肝病,在慢性斑块型银屑病患者中非常普遍。最近,减肥已成为一种强烈推荐的干预措施,以改善银屑病症状的严重程度、银屑病引起的慢性全身性炎症、银屑病相关心血管危险因素、生活质量和抗银屑病药物的疗效。本研究旨在评估12周低热量饮食干预对伴有慢性斑块和非酒精性脂肪肝的I级肥胖男性的天冬氨酸转氨酶、牛皮癣严重程度(通过牛皮癣面积和严重程度指数- PASI评估)、丙氨酸转氨酶、生活质量(通过皮肤病生活质量指数- DLQI评估)、甘油三酯、腰围(WC)和体重指数(BMI)的影响。材料和方法:60名年龄≥18岁的ⅰ类肥胖、慢性斑块性牛皮癣和非酒精性脂肪性肝病患者纳入研究。所有参与者被随机分为两组:第一组为低热量饮食组(30名男性接受免疫抑制药物,遵循低热量饮食,并通过每天15,000步的户外步行计划增加能量消耗,持续12周),第二组为对照组(30名男性只接受免疫抑制药物)。主要结果包括面积和严重程度指数的结果。体重、BMI、WC、实验室结果如甘油三酯、肝酶(丙氨酸转氨酶和天冬氨酸转氨酶)以及DLQI被认为是次要结局。结果:虽然对照组的测量变量没有显著改善,但低热量饮食组在所有测量变量上都有显著改善。结论:本研究的结果证实,12周的低热量饮食干预可以控制BMI,增加牛皮癣对药物的反应,改善生活质量。饮食干预可显著控制男性慢性斑块型银屑病和非酒精性脂肪肝患者肝酶(天冬氨酸和丙氨酸转氨酶)和甘油三酯升高。
{"title":"Effect of low-calorie diet on psoriasis severity index, triglycerides, liver enzymes, and quality of life in psoriatic patients with non-alcoholic fatty liver disease.","authors":"Ali Mohamed Ali Ismail,&nbsp;Ahmad Elsayed Saad,&nbsp;Ramy Salama Draz","doi":"10.5114/reum/162995","DOIUrl":"https://doi.org/10.5114/reum/162995","url":null,"abstract":"<p><strong>Introduction: </strong>Chronic-plaque psoriasis is a chronic inflammatory dermatological disease. Obesity comorbidities, including non-alcoholic fatty liver disease, are highly prevalent in patients with chronic-plaque psoriasis. Recently, weight loss has been a highly recommended intervention to improve the severity of psoriatic symptoms, psoriasis-induced chronic systemic inflammation, psoriasis-associated cardiovascular risk factors, quality of life, and the efficacy of anti-psoriatic drugs. This study was designed to assess the effect of a 12-week low-calorie-diet intervention on aspartate transaminase, psoriasis severity (assessed via Psoriasis Area and Severity Index - PASI), alanine transaminase, quality of life (assessed via Dermatology Life Quality Index - DLQI), triglycerides, waist circumference (WC), and body mass index (BMI) in class I obese men with chronic-plaque and non-alcoholic fatty liver disease.</p><p><strong>Material and methods: </strong>Sixty men with age ≥ 18 years with class I obesity and with chronic plaque psoriasis and non-alcoholic fatty liver disease were included in the study. All participants were randomly assigned to one of two groups: the first group as the low-calorie-diet group (30 men received immunosuppressive drugs, followed a low-calorie diet, and increased their energy expenditure through a daily 15,000-step outdoor walking program for 12 weeks) and the second as the control group (30 men received immunosuppressive drugs only). The primary outcome consisted of the results of the area and severity index. Weight, BMI, WC, laboratory results such as triglycerides, liver enzymes (alanine transaminase and aspartate transaminase) as well as DLQI were considered as secondary outcomes.</p><p><strong>Results: </strong>While no significant improvements were achieved in the measured variables of the control group, the low-calorie-diet group demonstrated significant improvement in all the measured variables.</p><p><strong>Conclusions: </strong>The results of the present study confirmed that 12-week low-calorie-diet intervention controls BMI, increases the response of psoriasis to pharmacological agents and improves the quality of life. Diet interventions significantly control the elevated hepatic enzymes (aspartate and alanine transaminases) and triglycerides in male patients with chronic-plaque psoriasis and non-alcoholic fatty liver disease.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"61 2","pages":"116-122"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e7/86/RU-61-162995.PMC10201385.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9516243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
The influence of growth hormone deficiency on bone health and metabolisms. 生长激素缺乏对骨骼健康和代谢的影响。
Q3 RHEUMATOLOGY Pub Date : 2023-01-01 Epub Date: 2023-08-31 DOI: 10.5114/reum/170244
Arnika Wydra, Izabella Czajka-Oraniec, Jakub Wydra, Wojciech Zgliczyński

Growth hormone (GH) is a key peptide hormone in the regulation of bone metabolism, through its systemic and paracrine action mediated directly as well as by insulin-like growth factor-1 (IGF-1). Growth hormone exerts pleiotropic effects leading to an increase in linear bone growth, accumulation of bone mineral content and preservation of peak bone mass. Furthermore, it influences protein, lipid, and carbohydrate metabolism.Growth hormone deficiency (GHD) causes a low bone turnover rate leading to reduced bone mineral density (BMD) and increased bone fragility. The results of GH insufficiency are the most pronounced among children as it negatively affects longitudinal bone growth, causing short stature and in adolescents, in whom it hinders the acquisition of peak bone mass. Most studies show that treatment with recombinant human growth hormone (rhGH) in GHD patients could improve BMD and decrease fracture risk. This review aims to summarize the pathophysiology, clinical picture and management of bone complications observed in GHD.

生长激素(GH)是调节骨代谢的关键肽激素,通过其直接介导的全身和旁分泌作用以及胰岛素样生长因子-1(IGF-1)。生长激素具有多效性作用,可增加骨的线性生长、骨矿物质含量的积累和峰值骨量的保持。此外,它还影响蛋白质、脂质和碳水化合物的代谢。生长激素缺乏(GHD)导致骨转换率低,导致骨密度(BMD)降低和骨脆性增加。生长激素不足的结果在儿童中最为明显,因为它对纵向骨生长产生负面影响,导致身材矮小,在青少年中,它阻碍了峰值骨量的获得。大多数研究表明,重组人生长激素(rhGH)治疗GHD患者可以改善骨密度,降低骨折风险。这篇综述旨在总结GHD中观察到的骨并发症的病理生理学、临床表现和处理。
{"title":"The influence of growth hormone deficiency on bone health and metabolisms.","authors":"Arnika Wydra,&nbsp;Izabella Czajka-Oraniec,&nbsp;Jakub Wydra,&nbsp;Wojciech Zgliczyński","doi":"10.5114/reum/170244","DOIUrl":"https://doi.org/10.5114/reum/170244","url":null,"abstract":"<p><p>Growth hormone (GH) is a key peptide hormone in the regulation of bone metabolism, through its systemic and paracrine action mediated directly as well as by insulin-like growth factor-1 (IGF-1). Growth hormone exerts pleiotropic effects leading to an increase in linear bone growth, accumulation of bone mineral content and preservation of peak bone mass. Furthermore, it influences protein, lipid, and carbohydrate metabolism.Growth hormone deficiency (GHD) causes a low bone turnover rate leading to reduced bone mineral density (BMD) and increased bone fragility. The results of GH insufficiency are the most pronounced among children as it negatively affects longitudinal bone growth, causing short stature and in adolescents, in whom it hinders the acquisition of peak bone mass. Most studies show that treatment with recombinant human growth hormone (rhGH) in GHD patients could improve BMD and decrease fracture risk. This review aims to summarize the pathophysiology, clinical picture and management of bone complications observed in GHD.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"61 4","pages":"239-247"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a6/62/RU-61-170244.PMC10515129.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41165745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Approach to prediction and receiver operating characteristic analysis of a regression model for assessing the severity of the course Lyme borreliosis in children. 评估儿童莱姆病病程严重程度的回归模型的预测方法和受试者工作特征分析。
Q3 RHEUMATOLOGY Pub Date : 2023-01-01 Epub Date: 2023-10-31 DOI: 10.5114/reum/173115
Svetlana Oleksiivna Nykytyuk, Andriy Stepanovych Sverstiuk, Serhiy Ivanovich Klymnyuk, Dmytro Stepanovych Pyvovarchuk, Yuri Bogdanovich Palaniza

Introduction: Lyme borreliosis (LB) is a multisystemic zoonotic disease transmitted by the bite of infected tick vectors.The aim of the study is to develop a mathematical model for predicting the risk of severity of Lyme disease by the risk factor of the disseminated form of LB in children who have had a tick attack. To test the effectiveness of the formula for predicting the development of the disseminated stage of LB, we built a receiver operating characteristic (ROC) curve and determined the specificity and sensitivity of our model. The results of the examination of 122 patients with the confirmed local and disseminated stages of LB were taken as a basis.

Material and methods: To build a prognostic model for prediction of the risk of the developing of the stage in LB predicting the risk of severity of course in Lyme borreliosis (PRSCLB), 122 children (aged 13 ±3 years) with LB were examined using multivariate regression analysis, including 52 boys and 70 girls. Groups of patients: 79 children with erythema migrans, 16 with Lyme arthritis, and 27 with nervous system involvement by LB. The quality of the prognostic model was checked by the Nagelkerke R Square (Nagelkerke R2) and the acceptability of this model was assessed using ROC analysis.

Results: The method of multivariate regression analysis for predicting severe course and organ and system damage in LB in children, taking into account the factors and variants of the disease itself, makes it possible to develop a mathematical model for predicting the relative response factors (RRF) of severe forms of Lyme disease and will improve the effectiveness of treatment. This will create all the prerequisites for high-quality preventive measures and reduce the relative response factors rate.The initial data for predicting the severity of LB were 28 factors. According to the results of regression analysis, 24 factors were included in the model for predicting the severity of LB.

Conclusions: The results of the study showed that the multifactorial model predicts the severity and organ and system damage in LB in children with an accuracy of 95%. The ROC curve, which was built on the basis of the results, has an area under the curve of 0.94, which indicates the high efficiency of the model.

简介:莱姆病是一种多系统的人畜共患疾病,由受感染的蜱虫叮咬传播。该研究的目的是建立一个数学模型,通过感染蜱虫的儿童传播型LB的危险因素来预测莱姆病严重程度的风险。为了检验该公式预测LB扩散阶段发展的有效性,我们建立了受试者工作特征(ROC)曲线,并确定了我们模型的特异性和敏感性。以122例确诊为局部和弥散性LB患者的检查结果为依据。材料与方法:采用多因素回归分析方法对122例(13±3岁)LB患儿(男52例,女70例)进行分析,以建立预测LB分期发展风险和预测PRSCLB病程严重程度风险的预后模型。患者组:迁移性红斑患儿79例,莱姆病患儿16例,LB累及神经系统患儿27例。采用Nagelkerke R平方(Nagelkerke R2)检查预后模型的质量,并采用ROC分析评估该模型的可接受性。结果:多因素回归分析预测儿童莱姆病严重病程和器官系统损害的方法,考虑疾病本身的因素和变异,可以建立预测莱姆病严重形式相对反应因子(RRF)的数学模型,提高治疗效果。这将为高质量的预防措施创造一切先决条件,并降低相对反应因子率。预测LB严重程度的初始数据为28个因素。根据回归分析结果,将24个因素纳入预测LB严重程度的模型。结论:本研究结果表明,多因素模型预测儿童LB的严重程度和器官系统损害的准确率为95%。在此基础上建立的ROC曲线曲线下面积为0.94,表明模型的效率较高。
{"title":"Approach to prediction and receiver operating characteristic analysis of a regression model for assessing the severity of the course Lyme borreliosis in children.","authors":"Svetlana Oleksiivna Nykytyuk, Andriy Stepanovych Sverstiuk, Serhiy Ivanovich Klymnyuk, Dmytro Stepanovych Pyvovarchuk, Yuri Bogdanovich Palaniza","doi":"10.5114/reum/173115","DOIUrl":"https://doi.org/10.5114/reum/173115","url":null,"abstract":"<p><strong>Introduction: </strong>Lyme borreliosis (LB) is a multisystemic zoonotic disease transmitted by the bite of infected tick vectors.The aim of the study is to develop a mathematical model for predicting the risk of severity of Lyme disease by the risk factor of the disseminated form of LB in children who have had a tick attack. To test the effectiveness of the formula for predicting the development of the disseminated stage of LB, we built a receiver operating characteristic (ROC) curve and determined the specificity and sensitivity of our model. The results of the examination of 122 patients with the confirmed local and disseminated stages of LB were taken as a basis.</p><p><strong>Material and methods: </strong>To build a prognostic model for prediction of the risk of the developing of the stage in LB predicting the risk of severity of course in Lyme borreliosis (PRSCLB), 122 children (aged 13 ±3 years) with LB were examined using multivariate regression analysis, including 52 boys and 70 girls. Groups of patients: 79 children with erythema migrans, 16 with Lyme arthritis, and 27 with nervous system involvement by LB. The quality of the prognostic model was checked by the Nagelkerke R Square (Nagelkerke R2) and the acceptability of this model was assessed using ROC analysis.</p><p><strong>Results: </strong>The method of multivariate regression analysis for predicting severe course and organ and system damage in LB in children, taking into account the factors and variants of the disease itself, makes it possible to develop a mathematical model for predicting the relative response factors (RRF) of severe forms of Lyme disease and will improve the effectiveness of treatment. This will create all the prerequisites for high-quality preventive measures and reduce the relative response factors rate.The initial data for predicting the severity of LB were 28 factors. According to the results of regression analysis, 24 factors were included in the model for predicting the severity of LB.</p><p><strong>Conclusions: </strong>The results of the study showed that the multifactorial model predicts the severity and organ and system damage in LB in children with an accuracy of 95%. The ROC curve, which was built on the basis of the results, has an area under the curve of 0.94, which indicates the high efficiency of the model.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"61 5","pages":"345-352"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10634403/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134649584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The 4DBODY system as a new tool for chest mobility assessment in patients with ankylosing spondylitis. 4DBODY系统作为强直性脊柱炎患者胸部活动能力评估的新工具。
Q3 RHEUMATOLOGY Pub Date : 2023-01-01 Epub Date: 2023-10-31 DOI: 10.5114/reum/173022
Teresa Sadura-Sieklucka, Daniel Szewczyk, Paweł Liberacki, Sławomir Paśko, Piotr Wojdasiewicz, Tomasz Targowski

Introduction: Ankylosing spondylitis (AS) is a chronic inflammatory, progressive disease, which leads to deterioration of chest and spine mobility and decrease of physical capacity with abnormal chest movement patterns. We aimed to assess the usefulness of the 4DBODY technology for evaluation of the effectiveness of AS treatment.

Material and methods: The 4DBODY technology was assessed on single AS patient with axial involvement. The patient was examined twice, before and after 14 days of rehabilitation. Physiotherapeutic and plethysmographic examinations were used, as well as angular measurement of spine curvatures and measurement of chest mobility. Chest activity measured using the 4DBODY system and the quality of movement were visualized.

Results: There was observed an increase of chest mobility from 18 mm to 27.9 mm (up 55%) in the 4DBODY system measurement. The quality of the chest movement also improved, the required phases of inspiration were synchronized. The angular position of the spine has also changed. The chest expansion improved from 25 mm to 50 mm measured on the level of the fourth intercostal space and from 30 mm to 50 mm at the Th10 level. Inspiratory and expiratory muscle strength increased respectively from 80% to 93% and from 46% to 86% of the predicted values. Total airway resistance (Rtot) - increase from 59% to 67%, whereas functional residual capacity (FRC) and total lung capacity (TLC) did not change significantly.

Conclusions: The new 4DBODY technology was found to be an effective method of examination and assessment of the effectiveness of rehabilitation of patients with AS.

简介:强直性脊柱炎(AS)是一种慢性炎症性进行性疾病,导致胸部和脊柱活动能力恶化,身体能力下降,胸部运动模式异常。我们的目的是评估4DBODY技术在评估AS治疗有效性方面的有用性。材料和方法:采用4DBODY技术对单个AS轴向受累患者进行评估。患者在康复前和14天后分别接受两次检查。使用了物理治疗和体积脉搏图检查,以及脊柱弯曲的角度测量和胸部活动度测量。使用4DBODY系统测量胸部活动并可视化运动质量。结果:在4DBODY系统测量中,观察到胸部活动度从18 mm增加到27.9 mm(增加55%)。胸部运动的质量也有所提高,所需的吸气阶段同步。脊柱的角度位置也发生了变化。在第四肋间隙水平胸廓扩张从25mm增加到50mm,在第10肋间隙水平胸廓扩张从30mm增加到50mm。吸气和呼气肌力分别从预测值的80%增加到93%,从46%增加到86%。总气道阻力(Rtot)从59%增加到67%,而功能残余容量(FRC)和总肺活量(TLC)无显著变化。结论:新的4DBODY技术是一种检测和评估AS患者康复效果的有效方法。
{"title":"The 4DBODY system as a new tool for chest mobility assessment in patients with ankylosing spondylitis.","authors":"Teresa Sadura-Sieklucka, Daniel Szewczyk, Paweł Liberacki, Sławomir Paśko, Piotr Wojdasiewicz, Tomasz Targowski","doi":"10.5114/reum/173022","DOIUrl":"https://doi.org/10.5114/reum/173022","url":null,"abstract":"<p><strong>Introduction: </strong>Ankylosing spondylitis (AS) is a chronic inflammatory, progressive disease, which leads to deterioration of chest and spine mobility and decrease of physical capacity with abnormal chest movement patterns. We aimed to assess the usefulness of the 4DBODY technology for evaluation of the effectiveness of AS treatment.</p><p><strong>Material and methods: </strong>The 4DBODY technology was assessed on single AS patient with axial involvement. The patient was examined twice, before and after 14 days of rehabilitation. Physiotherapeutic and plethysmographic examinations were used, as well as angular measurement of spine curvatures and measurement of chest mobility. Chest activity measured using the 4DBODY system and the quality of movement were visualized.</p><p><strong>Results: </strong>There was observed an increase of chest mobility from 18 mm to 27.9 mm (up 55%) in the 4DBODY system measurement. The quality of the chest movement also improved, the required phases of inspiration were synchronized. The angular position of the spine has also changed. The chest expansion improved from 25 mm to 50 mm measured on the level of the fourth intercostal space and from 30 mm to 50 mm at the Th10 level. Inspiratory and expiratory muscle strength increased respectively from 80% to 93% and from 46% to 86% of the predicted values. Total airway resistance (Rtot) - increase from 59% to 67%, whereas functional residual capacity (FRC) and total lung capacity (TLC) did not change significantly.</p><p><strong>Conclusions: </strong>The new 4DBODY technology was found to be an effective method of examination and assessment of the effectiveness of rehabilitation of patients with AS.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"61 5","pages":"353-359"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10634404/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134650852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Jagiellonian University and allied rheumatology centers across the country have launched Poland's first registry on inflammatory rheumatic diseases: How the Real World Evidence Registry in Rheumatic Diseases in Poland has finally become a fact. A long, steep road successfully completed. 雅盖隆尼亚大学和全国各地的风湿病学联合中心已经启动了波兰第一个炎症性风湿病注册:波兰风湿病的真实世界证据注册如何最终成为事实。一条又长又陡的路顺利地走完了。
Q3 RHEUMATOLOGY Pub Date : 2023-01-01 DOI: 10.5114/reum/161940
Mariusz Korkosz
Dear Editor, It was in early 2019 when a group of rheumatologists at Jagiellonian University Medical College had a vision of having Polish real world data instead of constantly quoting data from other countries. Such real world data are needed not only for scientific work, but also for improving the health care system and health care outcomes – our colleagues from the West have already seen this. Also big pharma listens to such data, which helps them set the pace for research and development of new drugs and improvement of drugs already in use by the rheumatology community. So, why do we not have our own registry in Poland? We have a lot of patients with rheumatic chronic inflammatory diseases, and current worldwide progress in medicine has been established on two pillars – randomized controlled trials (RCTs) and real world evidence (RWE). These two are a bridge to joint research and improvement of clinical achievements. Since RCTs are the domain of pharmaceutical companies, RWE remains attractive for us. Doesn’t such a large country deserve its own real world data in that case? Yes, of course – so that is why we decided to start. We did not want to duplicate the scheme – “we have an idea of a RWE Registry and once you give us money we will arrange it”. No, we adopted a different approach – we wrote a project application with Norwegian partners and received funding of PLN 7 million from Norway Grants via the National Centre for Research and Development in POLNOR Call 2019. The grant focused on improving health care and health outcomes of patients with inflammatory rheumatic diseases, both adults and children. Thus we got access to all Norwegian experience in RWE and their know-how in recording and navigating data flow for scientific but also practical purposes. Importantly, one of the key tasks was to create a high-quality register that would meet the requirements of data collection according to the philosophy of real world evidence that would be the basis for further scientific investigations and progress in clinical practice in Poland. So, all hands on deck, two clinical departments – Jagiellonian University Medical College Department of Rheumatology and Immunology and Sorlandet Hospital Division of Rheumatology from Norway and two IT companies – KAMBU from Krakow and DiagraphIT from Kristiansand, and the work began in early 2021 as PolNor Rheuma Project (www.polnorrheuma.com). The main undertaking at the beginning was to adapt a tool – the Norwegian IT program GoTreatIT (www. diagraphit.no) – for structured clinical data collection to the Polish environment. Once we had done this, we started enrolling patients in our database, and now we have more than 800 patients enrolled. For some, visits and data have been collected since the beginning of 2021. In the database we have evidence on the activity of the disease, imaging, treatment, side effects, accompanying diseases, and much more. In addition, we have a huge amount of data reported by the pa
{"title":"Jagiellonian University and allied rheumatology centers across the country have launched Poland's first registry on inflammatory rheumatic diseases: How the Real World Evidence Registry in Rheumatic Diseases in Poland has finally become a fact. A long, steep road successfully completed.","authors":"Mariusz Korkosz","doi":"10.5114/reum/161940","DOIUrl":"https://doi.org/10.5114/reum/161940","url":null,"abstract":"Dear Editor, It was in early 2019 when a group of rheumatologists at Jagiellonian University Medical College had a vision of having Polish real world data instead of constantly quoting data from other countries. Such real world data are needed not only for scientific work, but also for improving the health care system and health care outcomes – our colleagues from the West have already seen this. Also big pharma listens to such data, which helps them set the pace for research and development of new drugs and improvement of drugs already in use by the rheumatology community. So, why do we not have our own registry in Poland? We have a lot of patients with rheumatic chronic inflammatory diseases, and current worldwide progress in medicine has been established on two pillars – randomized controlled trials (RCTs) and real world evidence (RWE). These two are a bridge to joint research and improvement of clinical achievements. Since RCTs are the domain of pharmaceutical companies, RWE remains attractive for us. Doesn’t such a large country deserve its own real world data in that case? Yes, of course – so that is why we decided to start. We did not want to duplicate the scheme – “we have an idea of a RWE Registry and once you give us money we will arrange it”. No, we adopted a different approach – we wrote a project application with Norwegian partners and received funding of PLN 7 million from Norway Grants via the National Centre for Research and Development in POLNOR Call 2019. The grant focused on improving health care and health outcomes of patients with inflammatory rheumatic diseases, both adults and children. Thus we got access to all Norwegian experience in RWE and their know-how in recording and navigating data flow for scientific but also practical purposes. Importantly, one of the key tasks was to create a high-quality register that would meet the requirements of data collection according to the philosophy of real world evidence that would be the basis for further scientific investigations and progress in clinical practice in Poland. So, all hands on deck, two clinical departments – Jagiellonian University Medical College Department of Rheumatology and Immunology and Sorlandet Hospital Division of Rheumatology from Norway and two IT companies – KAMBU from Krakow and DiagraphIT from Kristiansand, and the work began in early 2021 as PolNor Rheuma Project (www.polnorrheuma.com). The main undertaking at the beginning was to adapt a tool – the Norwegian IT program GoTreatIT (www. diagraphit.no) – for structured clinical data collection to the Polish environment. Once we had done this, we started enrolling patients in our database, and now we have more than 800 patients enrolled. For some, visits and data have been collected since the beginning of 2021. In the database we have evidence on the activity of the disease, imaging, treatment, side effects, accompanying diseases, and much more. In addition, we have a huge amount of data reported by the pa","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"61 1","pages":"78-79"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/cb/e4/RU-61-161940.PMC10044039.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9214323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of the efficacy and safety of methotrexate alone or in combination with leflunomide in the treatment of juvenile idiopathic arthritis: a double-blind, placebo-controlled, randomized trial. 甲氨蝶呤单用或联合来氟米特治疗青少年特发性关节炎的疗效和安全性比较:一项双盲、安慰剂对照、随机试验
Q3 RHEUMATOLOGY Pub Date : 2023-01-01 DOI: 10.5114/reum/161317
Zahra Rezaieyazdi, Sahar Ravanshad, Mandana Khodashahi, Maliheh Bokaeian, Hassan Mehrad Majd, Masoumeh Salari

Introduction: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disorder in children. Although methotrexate (MTX) is the first line disease-modifying antirheumatic drug for JIA, many patients do not respond well or cannot tolerate MTX. The aim of this study was to compare the effect of combination therapy of MTX and leflunomide (LFN) with MTX in patients who do not respond to MTX.

Material and methods: Eighteen patients (2-20 years old) with polyarticular, oligoarticular or extended oligoarticular subtypes of JIA who did not respond to conventional JIA therapy participated in this double-blind, placebo-controlled, randomized trial. The intervention group received LFN and MTX for 3 months while the control group received oral placebo and MTX at a similar dose to the intervention group. Response to treatment was assessed every 4 weeks using the American College of Rheumatology Pediatric criteria (ACRPed) scale.

Results: Clinical criteria, including number of active joints and restricted joints, physician and patient global assessment, Childhood Health Assessment Questionnaire (CHAQ38) score, and serum erythrocyte sedimentation ratelevel, did not differ significantly between groups at baseline and at the end of the 4th and 8th weeks of treatment. Only the CHAQ38 score was significantly higher in the intervention group at the end of the 12th week of treatment. Analysis of the effect of treatment on study parameters revealed that only the global patient assessment score differed significantly between groups (p = 0.003).

Conclusions: The results of this study showed that combining LFN with MTX does not improve clinical outcomes of JIA and may increase side effects in patients who do not respond to MTX.

青少年特发性关节炎(JIA)是儿童中最常见的慢性风湿性疾病。虽然甲氨蝶呤(MTX)是JIA的一线疾病改善抗风湿药物,但许多患者对甲氨蝶呤反应不佳或不能耐受。本研究的目的是比较甲氨蝶呤和来氟米特(LFN)联合治疗与甲氨蝶呤对甲氨蝶呤无应答的患者的疗效。材料和方法:18例(2-20岁)的JIA多关节、少关节或扩展少关节亚型患者对传统JIA治疗无反应,参与了这项双盲、安慰剂对照、随机试验。干预组给予LFN和MTX治疗3个月,对照组给予与干预组相同剂量的口服安慰剂和MTX治疗。每4周使用美国风湿病学会儿科标准(ACRPed)量表评估对治疗的反应。结果:临床标准,包括活动关节和受限关节数量、医生和患者整体评估、儿童健康评估问卷(CHAQ38)评分和血清红细胞沉降率,在基线和治疗第4周和第8周结束时,两组之间无显著差异。在治疗第12周结束时,干预组只有CHAQ38评分显著高于对照组。治疗对研究参数的影响分析显示,两组之间只有患者总体评估评分有显著差异(p = 0.003)。结论:本研究结果表明,LFN联合MTX不能改善JIA的临床结果,并且可能增加对MTX无反应的患者的副作用。
{"title":"Comparison of the efficacy and safety of methotrexate alone or in combination with leflunomide in the treatment of juvenile idiopathic arthritis: a double-blind, placebo-controlled, randomized trial.","authors":"Zahra Rezaieyazdi,&nbsp;Sahar Ravanshad,&nbsp;Mandana Khodashahi,&nbsp;Maliheh Bokaeian,&nbsp;Hassan Mehrad Majd,&nbsp;Masoumeh Salari","doi":"10.5114/reum/161317","DOIUrl":"https://doi.org/10.5114/reum/161317","url":null,"abstract":"<p><strong>Introduction: </strong>Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disorder in children. Although methotrexate (MTX) is the first line disease-modifying antirheumatic drug for JIA, many patients do not respond well or cannot tolerate MTX. The aim of this study was to compare the effect of combination therapy of MTX and leflunomide (LFN) with MTX in patients who do not respond to MTX.</p><p><strong>Material and methods: </strong>Eighteen patients (2-20 years old) with polyarticular, oligoarticular or extended oligoarticular subtypes of JIA who did not respond to conventional JIA therapy participated in this double-blind, placebo-controlled, randomized trial. The intervention group received LFN and MTX for 3 months while the control group received oral placebo and MTX at a similar dose to the intervention group. Response to treatment was assessed every 4 weeks using the American College of Rheumatology Pediatric criteria (ACRPed) scale.</p><p><strong>Results: </strong>Clinical criteria, including number of active joints and restricted joints, physician and patient global assessment, Childhood Health Assessment Questionnaire (CHAQ38) score, and serum erythrocyte sedimentation ratelevel, did not differ significantly between groups at baseline and at the end of the 4<sup>th</sup> and 8<sup>th</sup> weeks of treatment. Only the CHAQ38 score was significantly higher in the intervention group at the end of the 12<sup>th</sup> week of treatment. Analysis of the effect of treatment on study parameters revealed that only the global patient assessment score differed significantly between groups (<i>p</i> = 0.003).</p><p><strong>Conclusions: </strong>The results of this study showed that combining LFN with MTX does not improve clinical outcomes of JIA and may increase side effects in patients who do not respond to MTX.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"61 1","pages":"4-12"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/28/6e/RU-61-161317.PMC10044028.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9230522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical characteristics of ankylosing spondylitis patients depending on neuropathic pain. 神经性疼痛对强直性脊柱炎患者临床特征的影响。
Q3 RHEUMATOLOGY Pub Date : 2023-01-01 DOI: 10.5114/reum/163223
Ivan Kedyk, Mykola Stanislavchuk

Introduction: Neuropathic pain (NP) in ankylosing spondylitis (AS) is an important factor that complicates patients' everyday activities and leads to a decrease of life quality. Detection and diagnosis of NP can be facilitated by the use of screening instruments, and the comparative assessment of the sensitivity of different scales is important for improving the diagnosis and personalizing the treatment of AS.The aim of the study was to analyze prevalence of NP in patients with AS and clinical features of AS patients depending on the presence of NP.

Material and methods: We examined 94 patients with NP and 48 patients without pain in AS using the following questionnaires: LANSS, DN4, StEP, BASFI, BASMI, BASDAI, HAQ, ASAS HI/EF and BAS-G.

Results: The prevalence of NP according to LANSS was 51.7% in women and 32.7% in men (p = 0.048); according to DN4 - 58.6% and 32.7%, respectively (p = 0.010). Disease activity and functional disability of the patients were higher in the group of patients with NP than in the group of patients without NP according to the BASDAI, BASFI, BASMI, HAQ, ASAS HI/EF and BAS-G. Significance of differences between groups was at the level of p < 0.01.

Conclusions: The prevalence of NP in AS is alarmingly high. Even with low scores on screening scales, patients showed signs of NP, which may indicate higher prevalence of NP. Neuropathic pain is more associated with the activity of the disease, greater loss of functional capacity and a decrease in indicators of the general state of health, which allows it to be considered as an aggravating factor regarding these manifestations.

导语:强直性脊柱炎(AS)患者的神经性疼痛(NP)是使患者日常活动复杂化、导致生活质量下降的重要因素。筛查仪器的使用有助于对NP的检测和诊断,比较评估不同量表的敏感性对提高AS的诊断和个性化治疗具有重要意义。本研究的目的是分析AS患者NP的患病率以及AS患者与NP相关的临床特征。材料与方法:采用LANSS、DN4、StEP、BASFI、BASMI、BASDAI、HAQ、ASAS HI/EF和BAS-G问卷对94例NP患者和48例无疼痛AS患者进行了调查。结果:根据LANSS, NP的患病率女性为51.7%,男性为32.7% (p = 0.048);DN4分别为58.6%和32.7% (p = 0.010)。根据BASDAI、BASFI、BASMI、HAQ、ASAS HI/EF和BAS-G, NP组患者的疾病活动性和功能失能均高于非NP组。组间差异在p < 0.01水平上具有显著性。结论:AS中NP的患病率高得惊人。即使在筛查量表上得分较低,患者也表现出NP的迹象,这可能表明NP的患病率较高。神经性疼痛更多地与疾病的活动性、更大程度的功能丧失和总体健康状况指标的下降有关,因此可以将其视为这些症状的加重因素。
{"title":"Clinical characteristics of ankylosing spondylitis patients depending on neuropathic pain.","authors":"Ivan Kedyk,&nbsp;Mykola Stanislavchuk","doi":"10.5114/reum/163223","DOIUrl":"https://doi.org/10.5114/reum/163223","url":null,"abstract":"<p><strong>Introduction: </strong>Neuropathic pain (NP) in ankylosing spondylitis (AS) is an important factor that complicates patients' everyday activities and leads to a decrease of life quality. Detection and diagnosis of NP can be facilitated by the use of screening instruments, and the comparative assessment of the sensitivity of different scales is important for improving the diagnosis and personalizing the treatment of AS.The aim of the study was to analyze prevalence of NP in patients with AS and clinical features of AS patients depending on the presence of NP.</p><p><strong>Material and methods: </strong>We examined 94 patients with NP and 48 patients without pain in AS using the following questionnaires: LANSS, DN4, StEP, BASFI, BASMI, BASDAI, HAQ, ASAS HI/EF and BAS-G.</p><p><strong>Results: </strong>The prevalence of NP according to LANSS was 51.7% in women and 32.7% in men (<i>p</i> = 0.048); according to DN4 - 58.6% and 32.7%, respectively (<i>p</i> = 0.010). Disease activity and functional disability of the patients were higher in the group of patients with NP than in the group of patients without NP according to the BASDAI, BASFI, BASMI, HAQ, ASAS HI/EF and BAS-G. Significance of differences between groups was at the level of <i>p</i> < 0.01.</p><p><strong>Conclusions: </strong>The prevalence of NP in AS is alarmingly high. Even with low scores on screening scales, patients showed signs of NP, which may indicate higher prevalence of NP. Neuropathic pain is more associated with the activity of the disease, greater loss of functional capacity and a decrease in indicators of the general state of health, which allows it to be considered as an aggravating factor regarding these manifestations.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"61 2","pages":"104-108"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ea/cb/RU-61-163223.PMC10201386.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9888096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Emotional and cognitive states of geriatric patients during the COVID-19 pandemic - an observational study. COVID-19大流行期间老年患者情绪和认知状态的观察性研究
Q3 RHEUMATOLOGY Pub Date : 2023-01-01 DOI: 10.5114/reum/168344
Teresa Sadura-Sieklucka, Joanna Szczuka, Tomasz Targowski

Introduction: The authors of the study assessed the emotional and cognitive state of geriatric patients during the COVID-19 pandemic and tried to answer the question: were there any differences in this state in geriatric patients at different stages of the pandemic?

Material and methods: The study included 518 patients of 60 years old and above of the Department of Geriatrics in Warsaw. To collect data, the following tools of psychological measurement were applied: the Mini-Mental State Examination scale and Geriatric Depression Scale. In order to test the differences in the means between the groups, a Chi-square test (with Yates's correction for continuity when the class size did not exceed 8 items) was used. For the comparison of the three groups, the Kruskal-Wallis (ANOVA) test was performed.

Results: It was found that the majority of geriatric patients (73% of respondents) do not show symptoms of depressed mood. But there are statistically significant differences in the results of the patients' cognitive state tests depending on the time of examination. Patients examined before the pandemic tended to demonstrate a better cognitive state than patients at the beginning of the pandemic and in its later stages. Nevertheless, there are no significant differences in the cognitive functioning of patients examined at the beginning and later in the pandemic.

Conclusions: The number of geriatric patients with symptoms of depression significantly increased when visits of relatives prohibition were introduced. However, the number of patients with depression returned to its previous level later in the pandemic.This phenomenon may indicate psychological adaptation to the situation. The presented results of observation suggest that the introduction of limitations is less important than the particular perception of one's situation and adaptation to that.

本研究的作者评估了COVID-19大流行期间老年患者的情绪和认知状态,并试图回答这样一个问题:在大流行的不同阶段,老年患者的情绪和认知状态是否存在差异?材料和方法:研究纳入华沙老年科60岁及以上患者518例。为了收集数据,使用了以下心理测量工具:简易精神状态检查量表和老年抑郁量表。为了检验组间均值的差异,使用卡方检验(当类别规模不超过8个项目时,使用Yates的连续性校正)。三组比较采用Kruskal-Wallis (ANOVA)检验。结果:大多数老年患者(73%)没有出现抑郁情绪的症状。但不同时间患者认知状态测试结果差异有统计学意义。在大流行之前接受检查的患者往往比大流行开始时和后期阶段的患者表现出更好的认知状态。然而,在大流行初期和后期接受检查的患者的认知功能没有显著差异。结论:实行探亲禁令后,出现抑郁症状的老年患者数量明显增加。然而,抑郁症患者的数量在大流行后期恢复到以前的水平。这种现象可能表明对这种情况的心理适应。所提出的观察结果表明,限制的引入不如对一个人的处境的特定感知和适应来得重要。
{"title":"Emotional and cognitive states of geriatric patients during the COVID-19 pandemic - an observational study.","authors":"Teresa Sadura-Sieklucka,&nbsp;Joanna Szczuka,&nbsp;Tomasz Targowski","doi":"10.5114/reum/168344","DOIUrl":"https://doi.org/10.5114/reum/168344","url":null,"abstract":"<p><strong>Introduction: </strong>The authors of the study assessed the emotional and cognitive state of geriatric patients during the COVID-19 pandemic and tried to answer the question: were there any differences in this state in geriatric patients at different stages of the pandemic?</p><p><strong>Material and methods: </strong>The study included 518 patients of 60 years old and above of the Department of Geriatrics in Warsaw. To collect data, the following tools of psychological measurement were applied: the Mini-Mental State Examination scale and Geriatric Depression Scale. In order to test the differences in the means between the groups, a Chi-square test (with Yates's correction for continuity when the class size did not exceed 8 items) was used. For the comparison of the three groups, the Kruskal-Wallis (ANOVA) test was performed.</p><p><strong>Results: </strong>It was found that the majority of geriatric patients (73% of respondents) do not show symptoms of depressed mood. But there are statistically significant differences in the results of the patients' cognitive state tests depending on the time of examination. Patients examined before the pandemic tended to demonstrate a better cognitive state than patients at the beginning of the pandemic and in its later stages. Nevertheless, there are no significant differences in the cognitive functioning of patients examined at the beginning and later in the pandemic.</p><p><strong>Conclusions: </strong>The number of geriatric patients with symptoms of depression significantly increased when visits of relatives prohibition were introduced. However, the number of patients with depression returned to its previous level later in the pandemic.This phenomenon may indicate psychological adaptation to the situation. The presented results of observation suggest that the introduction of limitations is less important than the particular perception of one's situation and adaptation to that.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"61 3","pages":"169-174"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d0/87/RU-61-168344.PMC10373168.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10286348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular mechanisms and potential applications of chondroitin sulphate in managing post-traumatic osteoarthritis. 硫酸软骨素治疗创伤后骨关节炎的分子机制及其潜在应用。
Q3 RHEUMATOLOGY Pub Date : 2023-01-01 Epub Date: 2023-10-31 DOI: 10.5114/reum/172211
Iryna Golovach, Dmytro Rekalov, Oleh Ye Akimov, Heorhii Kostenko, Viktoriia Kostenko, Artur Mishchenko, Natalia Solovyova, Vitalii Kostenko

Post-traumatic osteoarthritis (PTOA), a disorder of the synovium, subchondral bone, and cartilage that affects the entire joint, constitutes approximately 12% of all cases of symptomatic osteoarthritis. This review summarizes the pathogenetic mechanisms that underlie the positive influence of chondroitin sulphates (CSs) on PTOA as means of preventive and therapeutic treatment. Mechanisms of PTOA development involve chondrocytes undergoing various forms of cell death (apoptosis, pyroptosis, necroptosis, ferroptosis and/or necrosis). Chondroitin sulphates are a class of glycosaminoglycans that improve the structure and function of cartilage and subchondral bone, which is associated with their ability to decrease the activation of NF-κB and p38 MAPK, and up-regulate Nrf2. Standardized small fish extract (SSFE) is an example of the drugs that can attenuate NF-κB-mediated systemic inflammation, potentially helping to reduce joint inflammation and cartilage degradation, improve joint function, and alleviate pain and disability in patients with these conditions.

创伤后骨关节炎(PTOA)是一种滑膜、软骨下骨和软骨紊乱,影响整个关节,约占所有症状性骨关节炎病例的12%。本文综述了硫酸软骨素(CSs)作为预防和治疗手段对PTOA积极影响的发病机制。PTOA发生的机制涉及软骨细胞经历各种形式的细胞死亡(凋亡、焦亡、坏死、铁亡和/或坏死)。硫酸软骨素是一类糖胺聚糖,可以改善软骨和软骨下骨的结构和功能,这与其降低NF-κB和p38 MAPK的激活以及上调Nrf2的能力有关。标准化小鱼提取物(SSFE)是一种可以减轻NF-κ b介导的全身炎症的药物,可能有助于减少关节炎症和软骨退化,改善关节功能,减轻这些疾病患者的疼痛和残疾。
{"title":"Molecular mechanisms and potential applications of chondroitin sulphate in managing post-traumatic osteoarthritis.","authors":"Iryna Golovach, Dmytro Rekalov, Oleh Ye Akimov, Heorhii Kostenko, Viktoriia Kostenko, Artur Mishchenko, Natalia Solovyova, Vitalii Kostenko","doi":"10.5114/reum/172211","DOIUrl":"https://doi.org/10.5114/reum/172211","url":null,"abstract":"<p><p>Post-traumatic osteoarthritis (PTOA), a disorder of the synovium, subchondral bone, and cartilage that affects the entire joint, constitutes approximately 12% of all cases of symptomatic osteoarthritis. This review summarizes the pathogenetic mechanisms that underlie the positive influence of chondroitin sulphates (CSs) on PTOA as means of preventive and therapeutic treatment. Mechanisms of PTOA development involve chondrocytes undergoing various forms of cell death (apoptosis, pyroptosis, necroptosis, ferroptosis and/or necrosis). Chondroitin sulphates are a class of glycosaminoglycans that improve the structure and function of cartilage and subchondral bone, which is associated with their ability to decrease the activation of NF-κB and p38 MAPK, and up-regulate Nrf2. Standardized small fish extract (SSFE) is an example of the drugs that can attenuate NF-κB-mediated systemic inflammation, potentially helping to reduce joint inflammation and cartilage degradation, improve joint function, and alleviate pain and disability in patients with these conditions.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"61 5","pages":"395-407"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10634410/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134649588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Temporomandibular joint disorders in seronegative spondyloarthritis: what a rheumatologist needs to know? 血清阴性脊柱性关节炎的颞下颌关节紊乱:风湿病学家需要知道什么?
Q3 RHEUMATOLOGY Pub Date : 2023-01-01 Epub Date: 2023-10-31 DOI: 10.5114/reum/173078
Vasiliki Syrmou, Maria G Grammatikopoulou, Dimitrios P Bogdanos, Konstantinos T Mitsimponas

Temporomandibular joint (TMJ) can be affected in the context of spondyloarthritis (SpA) with detrimental impact on individuals' quality of life. Intra-articular inflammation, synovitis, enthesitis, disc displacement and cervical vertebrae malalignment are some of the pathophysiological phenomena involved. Temporomandibular joint disorders (TMD) incidence appears to be higher in patients with ankylosing spondylitis and psoriatic arthritis, especially when clinical evaluation includes not only imaging but relevant history, TMJ examination and diagnostic criteria for TMD. The Visual Analogue Scale (VAS) pain score and Health Assessment Questionnaire Disability Index (HAQ) quality of life score could be useful tools. Panoramic radiographs and ultrasound can be used for screening but in symptomatic patients magnetic resonance imaging (MRI) is preferable. Conservative management and early pharmacological treatment can prevent permanent joint impairment. For refractory cases, early referral to Legislation for Oral and Maxillofacial Surgery (OMFS) specialists is indicated. The aim of this narrative review is to address the involvement of TMJ in SpA and to encourage clinicians to incorporate TMJ assessment in their physical examination and basic screening.

在脊椎关节炎(SpA)的情况下,颞下颌关节(TMJ)可能受到影响,对个体的生活质量产生不利影响。关节内炎症、滑膜炎、椎体炎、椎间盘移位和颈椎错位是涉及的一些病理生理现象。强直性脊柱炎和银屑病关节炎患者的颞下颌关节疾病(Temporomandibular joint disorders, TMD)发病率似乎更高,尤其是当临床评估不仅包括影像学,还包括相关病史、TMJ检查和TMD的诊断标准时。视觉模拟量表(VAS)疼痛评分和健康评估问卷残疾指数(HAQ)生活质量评分可能是有用的工具。全景x线片和超声可用于筛查,但在有症状的患者中,磁共振成像(MRI)是首选。保守管理和早期药物治疗可预防永久性关节损伤。对于难治性病例,应及早转介到口腔颌面外科立法(OMFS)专家。这篇叙述性综述的目的是解决TMJ在SpA中的参与,并鼓励临床医生将TMJ评估纳入他们的身体检查和基本筛查。
{"title":"Temporomandibular joint disorders in seronegative spondyloarthritis: what a rheumatologist needs to know?","authors":"Vasiliki Syrmou, Maria G Grammatikopoulou, Dimitrios P Bogdanos, Konstantinos T Mitsimponas","doi":"10.5114/reum/173078","DOIUrl":"10.5114/reum/173078","url":null,"abstract":"<p><p>Temporomandibular joint (TMJ) can be affected in the context of spondyloarthritis (SpA) with detrimental impact on individuals' quality of life. Intra-articular inflammation, synovitis, enthesitis, disc displacement and cervical vertebrae malalignment are some of the pathophysiological phenomena involved. Temporomandibular joint disorders (TMD) incidence appears to be higher in patients with ankylosing spondylitis and psoriatic arthritis, especially when clinical evaluation includes not only imaging but relevant history, TMJ examination and diagnostic criteria for TMD. The Visual Analogue Scale (VAS) pain score and Health Assessment Questionnaire Disability Index (HAQ) quality of life score could be useful tools. Panoramic radiographs and ultrasound can be used for screening but in symptomatic patients magnetic resonance imaging (MRI) is preferable. Conservative management and early pharmacological treatment can prevent permanent joint impairment. For refractory cases, early referral to Legislation for Oral and Maxillofacial Surgery (OMFS) specialists is indicated. The aim of this narrative review is to address the involvement of TMJ in SpA and to encourage clinicians to incorporate TMJ assessment in their physical examination and basic screening.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"61 5","pages":"375-388"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10634408/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134649592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Reumatologia
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1